The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

Conditions

Primary Central Nervous System Lymphoma

Brief summary

The proportion of participants in whom the cancer gets worse, or who passed away, within 12 months after getting liso-cel.

Detailed description

The time it takes for the cancer to worsen, The time it takes for the participant to start a new cancer treatment, The time it takes for the participants to pass away, after they enroll into the study;, The proportion of participants with no detectable signs of cancer, The proportion of participants with improvement in signs (complete and partial responses), at any time after getting the liso-cel treatment and before the cancer gets worse, they start a new cancer treatment, or the study ends, How long the responses last, How the treatment affects the participants' quality of life, What kinds of health problems participants experience during the study, how severe they are, and how often they happen

Related papers

No related papers found yet.

Interventions

DRUGTEMOZOLOMIDE

DRUGMETHOTREXATE

DRUGPROCARBAZINE

DRUGCALCIUM FOLINATE

DRUGRITUXIMAB

DRUGFLUDARABINE

DRUGLisocabtagene maraleucel

DRUGCYCLOPHOSPHAMIDE

DRUGTOCILIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of participants in whom the cancer gets worse, or who passed away, within 12 months after getting liso-cel.	—

Secondary

Measure	Time frame
The time it takes for the cancer to worsen, The time it takes for the participant to start a new cancer treatment, The time it takes for the participants to pass away, after they enroll into the study;, The proportion of participants with no detectable signs of cancer, The proportion of participants with improvement in signs (complete and partial responses), at any time after getting the liso-cel treatment and before the cancer gets worse, they start a new cancer treatment, or the study ends, How long the responses last, How the treatment affects the participants' quality of life, What kinds of health problems participants experience during the study, how severe they are, and how often they happen	—

Measure

Time frame

The time it takes for the cancer to worsen, The time it takes for the participant to start a new cancer treatment, The time it takes for the participants to pass away, after they enroll into the study;, The proportion of participants with no detectable signs of cancer, The proportion of participants with improvement in signs (complete and partial responses), at any time after getting the liso-cel treatment and before the cancer gets worse, they start a new cancer treatment, or the study ends, How long the responses last, How the treatment affects the participants' quality of life, What kinds of health problems participants experience during the study, how severe they are, and how often they happen

—

Countries

France, Germany

Outcome results

None listed